These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23460711)

  • 1. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
    Aparicio T; Jouve JL; Teillet L; Gargot D; Subtil F; Le Brun-Ly V; Cretin J; Locher C; Bouché O; Breysacher G; Charneau J; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Mitry E
    J Clin Oncol; 2013 Apr; 31(11):1464-70. PubMed ID: 23460711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Aparicio T; Gargot D; Teillet L; Maillard E; Genet D; Cretin J; Locher C; Bouché O; Breysacher G; Seitz JF; Gasmi M; Stefani L; Ramdani M; Lecomte T; Auby D; Faroux R; Bachet JB; Lepère C; Khemissa F; Sobhani I; Boulat O; Mitry E; Jouve JL;
    Eur J Cancer; 2017 Mar; 74():98-108. PubMed ID: 27825697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Sastre J; Marcuello E; Masutti B; Navarro M; Gil S; Antón A; Abad A; Aranda E; Maurel J; Valladares M; Maestu I; Carrato A; Vicent JM; Díaz-Rubio E;
    J Clin Oncol; 2005 May; 23(15):3545-51. PubMed ID: 15908665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
    Aparicio T; Lavau-Denes S; Phelip JM; Maillard E; Jouve JL; Gargot D; Gasmi M; Locher C; Adhoute X; Michel P; Khemissa F; Lecomte T; Provençal J; Breysacher G; Legoux JL; Lepère C; Charneau J; Cretin J; Chone L; Azzedine A; Bouché O; Sobhani I; Bedenne L; Mitry E;
    Ann Oncol; 2016 Jan; 27(1):121-7. PubMed ID: 26487578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
    Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
    Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
    J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Aparicio T; Bouché O; Francois E; Retornaz F; Barbier E; Taieb J; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Bedenne L; Paillaud E;
    Eur J Cancer; 2018 Jul; 97():16-24. PubMed ID: 29777975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
    Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
    Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
    Ducreux M; Malka D; Mendiboure J; Etienne PL; Texereau P; Auby D; Rougier P; Gasmi M; Castaing M; Abbas M; Michel P; Gargot D; Azzedine A; Lombard-Bohas C; Geoffroy P; Denis B; Pignon JP; Bedenne L; Bouché O;
    Lancet Oncol; 2011 Oct; 12(11):1032-44. PubMed ID: 21903473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
    Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
    Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.